Matthew T Witkowski
Overview
Explore the profile of Matthew T Witkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, et al.
Blood
. 2024 Nov;
145(5):508-519.
PMID: 39561285
CD47 is overexpressed on the surface of many types of cancer cells, including T-cell acute lymphoblastic leukemia (T-ALL) cells. In this study, we have developed a diphtheria toxin (DT)-based bivalent...
2.
Garcia C, Miller-Awe M, Witkowski M
J Leukoc Biol
. 2024 Jan;
116(1):18-32.
PMID: 38243586
B cell acute lymphoblastic leukemia (B-ALL) arises from genetic alterations impacting B cell progenitors, ultimately leading to clinically overt disease. Extensive collaborative efforts in basic and clinical research have significantly...
3.
Iacobucci I, Zeng A, Gao Q, Garcia-Prat L, Baviskar P, Shah S, et al.
bioRxiv
. 2023 Dec;
PMID: 38106088
Sequencing of bulk tumor populations has improved genetic classification and risk assessment of B-ALL, but does not directly examine intratumor heterogeneity or infer leukemia cellular origins. We profiled 89 B-ALL...
4.
Contreras Yametti G, Evensen N, Schloss J, Aldebert C, Duan E, Zhang Y, et al.
Blood Adv
. 2023 May;
7(15):3928-3931.
PMID: 37196626
No abstract available.
5.
Ma C, Wang H, Liu L, Tong J, Witkowski M, Aifantis I, et al.
Res Sq
. 2023 May;
PMID: 37131801
Chimeric antigen receptor (CAR) T cell immunotherapy is promising for treatment of blood cancers; however, clinical benefits remain unpredictable, necessitating development of optimal CAR T cell products. Unfortunately, current preclinical...
6.
Battistello E, Hixon K, Comstock D, Collings C, Chen X, Rodriguez Hernaez J, et al.
Mol Cell
. 2023 Mar;
83(8):1216-1236.e12.
PMID: 36944333
Highly coordinated changes in gene expression underlie T cell activation and exhaustion. However, the mechanisms by which such programs are regulated and how these may be targeted for therapeutic benefit...
7.
Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker C, et al.
Nat Cancer
. 2023 Jan;
4(1):149.
PMID: 36658429
No abstract available.
8.
Liu L, Ma C, Zhang Z, Witkowski M, Aifantis I, Ghassemi S, et al.
J Immunother Cancer
. 2023 Jan;
10(12).
PMID: 36600553
Background: Adaptive CD19-targeted chimeric antigen receptor (CAR) T-cell transfer has become a promising treatment for leukemia. Although patient responses vary across different clinical trials, reliable methods to dissect and predict...
9.
Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker C, et al.
Nat Cancer
. 2022 Dec;
4(1):27-42.
PMID: 36581735
Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and limited treatment options. Here we provide a comprehensive census of the bone marrow immune microenvironment in adult and...
10.
Witkowski M, Lee S, Wang E, Lee A, Talbot A, Ma C, et al.
Nat Immunol
. 2022 Sep;
23(10):1424-1432.
PMID: 36138187
B cell progenitor acute lymphoblastic leukemia (B-ALL) treatment has been revolutionized by T cell-based immunotherapies-including chimeric antigen receptor T cell therapy (CAR-T) and the bispecific T cell engager therapeutic, blinatumomab-targeting...